Field Medical has successfully raised $35 million in a Series B venture capital funding round, bringing its total fundraising to $75 million, to support the launch of a pivotal trial for its cardiac pulsed field ablation system.

The Series B funding was co-led by BioStar Capital and Cue Growth, influenced by strong pilot data presented at the 2025 Heart Rhythm Society meeting in San Diego.

This latest funding follows a previous $40 million Series A round that closed in April 2025, with the new funds designated for starting the pivotal Veritas trial and advancing the FieldForce system's development.

Headquartered in Cardiff-by-the-Sea, California, Field Medical aims to address significant unmet needs in treating ventricular tachycardia with its innovative FieldForce platform.

Founder and CEO Steven Mickelsen highlighted the unmet clinical demand in the ventricular tachycardia segment, drawing parallels to the early days of the atrial fibrillation market.

Mickelsen, who previously invented the Farapulse PFA system for atrial fibrillation, established Field Medical in 2022 to focus on developing PFA technology specifically for ventricular tachycardia, a dangerous heart rhythm that can lead to sudden death.

Promising results presented at the Heart Rhythm Society indicated that 78% of patients treated with the FieldForce approach experienced freedom from symptoms, although two patients experienced worsening heart failure.

At the Heart Rhythm Society meeting, Field Medical showcased eight presentations, including a significant first-in-human study on ventricular tachycardia driven by scar tissue.

Pulsed field ablation (PFA) has gained traction among physicians for treating atrial fibrillation due to its potential for safety and efficiency compared to traditional ablation methods.

Louis Cannon, a physician and investor from BioStar Capital, praised Field Medical for addressing significant challenges in cardiology and emphasized the urgency of their innovative solutions.

Mickelsen expressed confidence in their next-generation therapy designed for speed, precision, and significant clinical advancements in ventricular tachycardia care for high-risk patients.